What is Opgen's earnings per share (EPS)?

Opgen (OPGN) reported diluted earnings per share of $2.32 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Opgen Financials

OPGN

FY2025 annual

Revenue $30.2M +481.2% YoY

Net Income $23.6M +97.0% YoY

EPS (Diluted) $2.32 YoY not available

Free Cash Flow -$1.2M YoY not available

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported Jun 12, 2026 Currency USD FYE December

Opgen (OPGN) reported $30.2M in revenue for fiscal year 2025, up 481.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI OPGN FY2025 2026-08-30

Reported earnings have become highly profitable on paper while cash conversion and near-term balance-sheet capacity move the other way.

Net income increased from $12.0M in FY2024 to $23.6M in FY2025, but operating cash flow remained negative at -$4.9M and -$1.2M, respectively. The narrower cash shortfall means reported profitability still did not translate into cash generation, making earnings quality the central operating question.

Operating margin jumped from 6.3% in FY2024 to 79.6% in FY2025, a step-change in reported economics rather than ordinary incremental scaling. FY2025 disclosed only $3.1M of SG&A and $7K of R&D, leaving the source of the unusually high margin unclear because cost of revenue is not reported.

The short-term funding position weakened sharply: current ratio fell from 4.2x in FY2024 to 0.2x in FY2025, so balance-sheet expansion did not improve near-term coverage. In FY2025, current liabilities reached $4.6M against current assets of $988K, indicating that reported assets were not matched by readily available current resources.

Financial Health Signals

Financial health score not available

Opgen does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/7

Opgen passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality No Cash Backing

$0.05used

For every $1 of reported earnings, Opgen used $0.05 of operating cash (-$1.2M OCF vs $23.6M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.

Interest Coverage Safe

2,136.78x

Opgen earns $2,136.78 in operating income for every $1 of interest expense ($24.0M vs $11K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$30.2M

YoY+481.2%

5Y CAGR+48.3%

10Y CAGR+25.3%

Opgen generated $30.2M in revenue in fiscal year 2025. This represents an increase of 481.2% from the prior year.

EBITDA

$24.2M

YoY+4748.9%

Opgen's EBITDA was $24.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 4748.9% from the prior year.

Net Income

$23.6M

YoY+97.0%

Opgen reported $23.6M in net income in fiscal year 2025. This represents an increase of 97.0% from the prior year.

EPS (Diluted)

$2.32

Opgen earned $2.32 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

-$1.2M

Opgen recorded an outflow of $1.2M in free cash flow in fiscal year 2025, representing a cash shortfall after capex.

Cash & Debt

$531K

YoY-59.5%

5Y CAGR-47.5%

10Y CAGR-23.6%

Opgen held $531K in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

10M

Opgen had 10M shares outstanding in fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Operating Margin

79.6%

YoY+73.3pp

Opgen's operating margin was 79.6% in fiscal year 2025, reflecting core business profitability. This is up 73.3 percentage points from the prior year.

Net Margin

78.2%

Opgen's net profit margin was 78.2% in fiscal year 2025, showing the share of revenue converted to profit. No change is given against fiscal year 2024: its reported ratio is above 100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

74.1%

YoY-88.4pp

Opgen's ROE was 74.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 88.4 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending

$7K

YoY-86.5%

5Y CAGR-76.9%

10Y CAGR-49.4%

Opgen invested $7K in research and development in fiscal year 2025. This represents a decrease of 86.5% from the prior year.

Capital Expenditures

$50K

Opgen invested $50K in capex in fiscal year 2025, funding long-term assets and infrastructure.

Share Buybacks

Not reported for fiscal year 2025.

OPGN Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

OPGN quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14
Revenue	N/A	$30.2M+481.2%	$5.2M+52.0%	$3.4M+31.1%	$2.6M-39.5%	$4.3M+2.2%	$4.2M+20.5%	$3.5M+18.7%	$2.9M-8.2%	$3.2M-20.2%	$4.0M+27.5%	$3.2M-23.5%	$4.1M
Cost of Revenue	N/A	N/A	N/A	$3.1M-7.1%	$3.3M+44.6%	$2.3M	N/A	N/A	N/A	$1.6M-2.8%	$1.7M+40.6%	$1.2M+177.2%	$426K
Gross Profit	N/A	N/A	N/A	$334K+146.9%	-$712K-135.4%	$2.0M	N/A	N/A	N/A	$1.6M-32.5%	$2.4M+19.7%	$2.0M-46.6%	$3.7M
R&D Expenses	N/A	$7K-86.5%	$49K-99.0%	$4.7M-42.1%	$8.2M-25.1%	$10.9M+9.5%	$10.0M+94.6%	$5.1M-9.8%	$5.7M-17.5%	$6.9M-20.1%	$8.6M+43.5%	$6.0M+37.4%	$4.4M
SG&A Expenses	N/A	$3.1M-31.0%	$4.5M-43.8%	$8.1M-9.0%	$8.9M-10.6%	$9.9M+12.9%	$8.8M+40.8%	$6.3M-11.6%	$7.1M+5.6%	$6.7M+1.4%	$6.6M+13.2%	$5.8M+152.3%	$2.3M
Operating Income	N/A	$24.0M+7299.7%	$325K	N/A	-$34.6M-48.5%	-$23.3M-2.4%	-$22.7M-85.1%	-$12.3M+6.9%	-$13.2M+13.7%	-$15.3M+19.7%	-$19.0M-26.2%	-$15.1M-170.6%	-$5.6M
Interest Expense	N/A	$11K+48.8%	$8K-99.6%	$1.8M-43.5%	$3.3M-32.1%	$4.8M+41.2%	$3.4M+1712.5%	$188K-1.9%	$191K-18.1%	$234K+62.9%	$143K-92.0%	$1.8M+1517.8%	$111K
Income Tax	N/A	$814K+360.7%	$177K	N/A	N/A	$44K-66.9%	$132K	$0	$0	$0	$0+100.0%	-$129K	$0
Net Income	N/A	$23.6M+97.0%	$12.0M	N/A	-$37.3M-7.1%	-$34.8M-32.8%	-$26.2M-110.6%	-$12.4M+6.9%	-$13.4M+13.3%	-$15.4M+19.6%	-$19.2M-10.5%	-$17.4M-206.0%	-$5.7M
EPS (Diluted)	—	$2.32	$2.30	-$41.47	-$152.70	-$22.89	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$0	N/A	N/A	$4.0M	$0	N/A	N/A	$28K
R&D Expenses	$2K	N/A	N/A	N/A	N/A	N/A	$488-97.9%	$23K
SG&A Expenses	$798K	N/A	$702K+18.0%	$595K+15.9%	$513K	N/A	$769K-51.0%	$1.6M
Operating Income	-$805K	N/A	-$702K-120.6%	$3.4M+750.8%	-$523K	N/A	-$784K+49.3%	-$1.5M
Interest Expense	$995	N/A	$4K+141.3%	$2K-49.9%	$3K	N/A	$3K+200.1%	$1K
Net Income	-$711K	N/A	-$609K-117.3%	$3.5M+960.0%	-$408K	N/A	$8.9M+666.6%	-$1.6M
EPS (Diluted)	-$0.06	N/A	-$0.06-117.6%	$0.34+950.0%	-$0.04	N/A	$1.35	-$1.18

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax.

OPGN Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

OPGN quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14
Total Assets	$38.1M+285.8%	$9.9M+424.0%	$1.9M-92.7%	$25.8M-64.0%	$71.7M+44.1%	$49.8M+377.4%	$10.4M+16.4%	$9.0M+35.2%	$6.6M-26.3%	$9.0M-34.7%	$13.8M+418.1%	$2.7M
Current Assets	$988K-62.7%	$2.6M+67.7%	$1.6M-85.2%	$10.7M-73.2%	$39.7M+135.3%	$16.9M+153.3%	$6.7M+15.3%	$5.8M+65.1%	$3.5M-38.4%	$5.7M-42.5%	$9.9M+476.9%	$1.7M
Cash & Equivalents	$531K-59.5%	$1.3M+13.8%	$1.2M-84.5%	$7.4M-79.4%	$36.1M+170.1%	$13.4M+393.3%	$2.7M-40.8%	$4.6M+147.5%	$1.8M-55.1%	$4.1M-47.3%	$7.8M+942.6%	$750K
Inventory	N/A	N/A	N/A	$3.6M-22.6%	$4.7M+48.5%	$3.2M+570.6%	$473K-13.0%	$544K+1.9%	$533K-23.0%	$692K-16.2%	$826K+123.4%	$370K
Accounts Receivable	$249K+750.3%	$29K-71.7%	$103K-79.9%	$514K-56.1%	$1.2M+79.5%	$653K+15.0%	$568K+51.9%	$374K-53.8%	$810K+49.2%	$542K-20.1%	$679K+34.7%	$504K
Goodwill	N/A	N/A	N/A	$0-100.0%	$7.5M-7.1%	$8.0M+1235.6%	$601K0.0%	$601K0.0%	$601K0.0%	$601K-5.8%	$638K	$0
Total Liabilities	$6.2M+149.7%	$2.5M-81.5%	$13.4M-26.3%	$18.2M-40.1%	$30.4M+6.6%	$28.6M+366.0%	$6.1M+8.6%	$5.6M+8.1%	$5.2M-10.3%	$5.8M-7.2%	$6.3M-41.6%	$10.7M
Current Liabilities	$4.6M+618.0%	$634K-94.4%	$11.4M+7.8%	$10.6M-46.8%	$19.9M+170.2%	$7.4M+49.3%	$4.9M+12.7%	$4.4M-8.5%	$4.8M-9.1%	$5.3M+14.9%	$4.6M-23.8%	$6.0M
Long-Term Debt	N/A	N/A	N/A	$4.9M-32.4%	$7.2M-63.0%	$19.4M+5782.1%	$329K	N/A	N/A	N/A	N/A	N/A
Total Equity	$31.9M+331.6%	$7.4M+163.8%	-$11.6M-252.6%	$7.6M-81.6%	$41.2M+94.5%	$21.2M+393.6%	$4.3M+29.8%	$3.3M+136.2%	$1.4M-55.8%	$3.2M-57.7%	$7.5M+192.9%	-$8.1M
Retained Earnings	-$269.9M+8.0%	-$293.5M+3.9%	-$305.5M-12.0%	-$272.8M-15.8%	-$235.5M-17.3%	-$200.7M-15.0%	-$174.5M-7.7%	-$162.1M-9.0%	-$148.7M-11.6%	-$133.3M-16.8%	-$114.1M-17.9%	-$96.8M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$37.5M-1.6%	$38.1M+201.1%	$12.6M-4.6%	$13.2M+40.6%	$9.4M-4.5%	$9.9M+80.3%	$5.5M+90.6%	$2.9M
Current Assets	$437K-55.8%	$988K-82.1%	$5.5M-9.7%	$6.1M+173.3%	$2.2M-15.5%	$2.6M-17.7%	$3.2M+461.7%	$573K
Cash & Equivalents	$79K-85.2%	$531K+28.3%	$414K-50.2%	$832K-25.3%	$1.1M-15.1%	$1.3M-19.7%	$1.6M+871.5%	$168K
Accounts Receivable	$254K+2.0%	$249K-93.8%	$4.0M+0.1%	$4.0M+11745.8%	$34K+16.5%	$29K+19.9%	$24K-3.9%	$25K
Total Liabilities	$6.2M0.0%	$6.2M+149.8%	$2.5M-3.8%	$2.6M+9.0%	$2.4M-4.7%	$2.5M-0.1%	$2.5M-82.9%	$14.5M
Current Liabilities	$4.6M+1.2%	$4.6M+481.9%	$782K-5.4%	$827K+46.8%	$563K-11.1%	$634K+7.5%	$590K-95.3%	$12.6M
Total Equity	$31.3M-1.9%	$31.9M+213.6%	$10.2M-4.8%	$10.7M+51.2%	$7.1M-4.4%	$7.4M+147.2%	$3.0M+125.6%	-$11.7M
Retained Earnings	-$270.6M-0.3%	-$269.9M+7.3%	-$291.0M-0.2%	-$290.4M+1.2%	-$293.9M-0.1%	-$293.5M+1.5%	-$297.9M+2.9%	-$306.8M

Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.

OPGN Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

OPGN quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14
Operating Cash Flow	-$1.4M	-$1.2M+75.7%	-$4.9M+66.0%	-$14.3M+30.0%	-$20.4M+4.8%	-$21.5M+8.2%	-$23.4M-103.4%	-$11.5M-3.9%	-$11.1M+22.6%	-$14.3M+17.1%	-$17.3M-20.8%	-$14.3M-165.1%	-$5.4M
Capital Expenditures	N/A	$50K	N/A	$800K+35.5%	$591K-70.2%	$2.0M+1421.7%	$130K+309.6%	$32K-78.5%	$148K-46.6%	$277K+124.2%	$124K-33.3%	$185K+368.7%	$40K
Free Cash Flow	N/A	-$1.2M	N/A	-$15.1M+28.1%	-$21.0M+10.3%	-$23.5M+0.3%	-$23.5M-103.9%	-$11.5M-2.8%	-$11.2M+23.0%	-$14.6M+16.1%	-$17.4M-20.1%	-$14.5M-166.6%	-$5.4M
Investing Cash Flow	N/A	-$49K	N/A	-$800K-35.5%	-$591K+70.2%	-$2.0M-86.5%	-$1.1M+57.5%	-$2.5M-1722.3%	-$137K+50.4%	-$277K	N/A	N/A	N/A
Financing Cash Flow	$500K	$497K-90.1%	$5.0M-39.9%	$8.4M+224.3%	-$6.7M-114.2%	$47.5M+39.2%	$34.1M+180.1%	$12.2M-12.1%	$13.8M+12.1%	$12.3M	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$364K-77.5%	-$205K+38.5%	-$333K+38.0%	-$538K-399.8%	-$108K+53.7%	-$232K+91.8%	-$2.8M-293.4%	-$720K
Financing Cash Flow	-$87K-121.0%	$414K+593.0%	-$84K-132.8%	$257K+384.2%	-$90K0.0%	-$90K-102.1%	$4.3M+592.3%	$621K

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.

OPGN Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

OPGN quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14
Gross Margin	N/A	N/A	9.8%+37.1pp	-27.3%-74.0pp	46.7%	N/A	N/A	N/A	49.8%-9.0pp	58.8%-3.8pp	62.6%-27.1pp	89.7%
Operating Margin	79.6%+73.3pp	6.3%	N/A	-1325.8%	-540.5%	-539.1%	-350.8%	-447.3%	-475.4%	-472.2%	-476.9%	-134.9%
Net Margin	78.2%	230.8%	N/A	-1430.0%	-808.3%	-621.9%	-355.8%	-453.7%	-480.2%	-476.1%	-549.5%	-137.4%
Return on Equity	74.1%-88.4pp	162.5%	N/A	-492.1%-407.7pp	-84.4%+39.3pp	-123.7%+166.2pp	-289.9%+114.1pp	-404.0%+696.6pp	-1100.6%-495.5pp	-605.1%-373.5pp	-231.6%	N/A
Return on Assets	62.1%-59.5pp	121.6%	N/A	-144.4%-95.9pp	-48.6%+4.1pp	-52.7%+66.7pp	-119.4%+29.9pp	-149.4%+83.6pp	-232.9%-19.6pp	-213.3%-87.2pp	-126.1%+87.5pp	-213.6%
Current Ratio	0.22-4.0x	4.18+4.0x	0.14-0.9x	1.01-1.0x	2.00-0.3x	2.29+0.9x	1.350.0x	1.32+0.6x	0.73-0.3x	1.08-1.1x	2.15+1.9x	0.28
Debt-to-Equity	0.19-0.1x	0.34	N/A	0.64+0.5x	0.17-0.7x	0.91+0.8x	0.08-1.6x	1.71-2.0x	3.73+1.9x	1.84+1.0x	0.84	N/A
FCF Margin	-4.1%	N/A	-442.3%	-807.0%	-544.9%	-558.2%	-329.8%	-380.9%	-454.1%	-431.6%	-458.0%	-131.5%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Margin	N/A	N/A	N/A	85.1%	N/A	N/A	N/A	-5526.1%
Net Margin	N/A	N/A	N/A	87.8%	N/A	N/A	N/A	-5629.8%
Return on Equity	-2.3%	N/A	-6.0%-38.9pp	32.9%+38.7pp	-5.8%	N/A	299.1%	N/A
Return on Assets	-1.9%	N/A	-4.8%-31.3pp	26.5%+30.8pp	-4.3%	N/A	163.3%+218.2pp	-54.9%
Current Ratio	0.09-0.1x	0.22-6.8x	7.06-0.3x	7.39+3.4x	3.97-0.2x	4.18-1.3x	5.46+5.4x	0.05
Debt-to-Equity	0.200.0x	0.190.0x	0.240.0x	0.24-0.1x	0.340.0x	0.34-0.5x	0.83	N/A

Not reported in any period shown, so not listed: Gross Margin, FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Note: The current ratio is below 1.0 (0.22), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Motus Gi Hldgs Inc MOTS

$435K

Thermogenesis Holdings Inc THMO

$5.4M

Micron Solutions MICR

$634

CS Diagnostics CSDX

$2.6M

Pressure Bio PBIO

$4K

Where Opgen Ranks

Frequently Asked Questions

What is Opgen's annual revenue?

Opgen (OPGN) reported $30.2M in total revenue for fiscal year 2025. This represents a 481.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Opgen's revenue growing?

Opgen (OPGN) revenue grew by 481.2% year-over-year, from $5.2M to $30.2M in fiscal year 2025.

Is Opgen profitable?

Yes, Opgen (OPGN) reported a net income of $23.6M in fiscal year 2025, with a net profit margin of 78.2%.

What is Opgen's EBITDA?

Opgen (OPGN) had EBITDA of $24.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Opgen's operating margin?

Opgen (OPGN) had an operating margin of 79.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Opgen's net profit margin?

Opgen (OPGN) had a net profit margin of 78.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Opgen's return on equity (ROE)?

Opgen (OPGN) has a return on equity of 74.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Opgen's free cash flow?

Opgen (OPGN) recorded an outflow of $1.2M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Opgen's operating cash flow?

Opgen (OPGN) recorded an outflow of $1.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Opgen's total assets?

Opgen (OPGN) had $38.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Opgen's capital expenditures?

Opgen (OPGN) invested $50K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Opgen spend on research and development?

Opgen (OPGN) invested $7K in research and development during fiscal year 2025.

How many shares does Opgen have outstanding?

Opgen (OPGN) had 10M shares outstanding as of fiscal year 2025.

What is Opgen's current ratio?

Opgen (OPGN) had a current ratio of 0.22 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Opgen's debt-to-equity ratio?

Opgen (OPGN) had a debt-to-equity ratio of 0.19 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Opgen's return on assets (ROA)?

Opgen (OPGN) had a return on assets of 62.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Opgen's Piotroski F-Score?

Opgen (OPGN) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Opgen's earnings high quality?

For every $1 of reported earnings, Opgen (OPGN) used $0.05 of operating cash (-$1.2M OCF vs $23.6M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Opgen cover its interest payments?

Opgen (OPGN) has an interest coverage ratio of 2,136.78x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.